Promising Advances in Osteoporosis Treatment with PEPITEM Molecule
New research highlights the PEPITEM molecule's potential to promote bone growth, reduce bone loss, and improve vascularization in osteoporosis treatment. A promising step towards innovative therapies.
Recent research from the University of Birmingham in the UK has unveiled the potential of the PEPITEM molecule as a novel therapeutic for osteoporosis. Scientists have identified specific bioactive sequences within PEPITEM and demonstrated its ability to counteract key pathological changes associated with osteoporosis. Published in the journal Biomedicine & Pharmacotherapy, the study shows that the full PEPITEM molecule not only reduces bone resorption and enhances bone formation but also stimulates angiogenesis—the growth of new blood vessels within bone tissue.
The research team, led by Professor Helen McGettrick and Dr. Amy Naylor, investigated the effects of PEPITEM on bone cells and tissues. They found that different segments of the molecule influence distinct processes: some fragments promote osteoblast maturation (bone formation), while others inhibit osteoclast (bone breakdown) activity. Tests on bone organoids and animal models confirmed that the complete PEPITEM peptide is essential for inducing comprehensive positive effects on bone architecture and strength.
Another vital discovery was that PEPITEM enhances vascularization in bones, specifically increasing density of type-H vessels crucial for bone health. This process involves PEPITEM interacting with the NCAM-1 receptor on osteoblasts, encouraging the growth of blood vessels that support bone regeneration.
Professor McGettrick emphasized the significance of these findings, highlighting PEPITEM's dual action in promoting bone formation and reducing bone loss as an advantage over existing osteoporosis drugs. The research team is now seeking collaborations to advance this promising molecule towards drug development, with the goal of providing a new treatment option for osteoporosis and related bone disorders.
Originating in 2015, PEPITEM is a naturally occurring peptide initially studied for its role in immune regulation. Its broad therapeutic potential now extends to inflammation, immune-mediated diseases, obesity, and notably, bone health. This research underscores the importance of further investigating PEPITEM’s mechanisms and its potential to transform osteoporosis management.
Source: https://medicalxpress.com/news/2025-09-osteoporosis-pepitem-molecule-bone-growth.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
FDA Approves Essilor Stellest Lenses to Help Young Children Manage Myopia
The FDA has approved Essilor Stellest eyeglass lenses for children aged 6-12 to help slow myopia progression and improve eye health during critical growth years.
Understanding the Impact of the New Pandemic Treaty on Global Health Security
The WHO Pandemic Agreement, adopted in 2025, marks a major step towards strengthening global health security through better coordination, early detection, and equitable access to health resources for future pandemics.